Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synthroid marketing settlement

Executive Summary

Pennsylvania's PACE program enters $6.2 mil. settlement with Abbott on Synthroid litigation regarding suppression of information from the "Dong study," which found levothyroxine generics to be bioequivalent to Synthroid. Knoll, which was acquired by Abbott in early 2001, has already entered into a $87 mil. settlement with approximately 778,000 consumer settlement class members (1"The Pink Sheet" Aug. 14, 2000, p. 28). Knoll in 1999 also entered into a $48.1 mil. settlement with 37 state Attorneys General after they accused Knoll of blocking publication of the "Dong study" (2"The Pink Sheet" Aug. 2, 1999, p. 36)...

You may also be interested in...

GSK Faces New York Suit Over Paxil: Publish Or Punish?

GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer

Knoll Synthroid

Marketing litigation settlement establishes $87 mil. consumer class fund to provide "approximately 778,000 consumer settlement class members least $84 for each claimant who bought Synthroid before 1995 and $55 for those who bought it starting in 1995," Chicago federal court Judge Elaine Bucklo ruled Aug. 4. The class action suits cited Knoll's delay of publication of a Dong et al. study that found certain branded and generic levothyroxine sodium products were bioequivalent to Knoll's thyroid medication. Under the settlement, about $46 mil. will also be paid to third-party payer class members

Knoll Synthroid settlement

Company agrees to provide $41.8 mil. to states for "consumer education, litigation, public protection or local consumer aid funds" as part of a settlement agreement with 37 state Attorneys General. The states initiated litigation relating to Knoll's blocking publication of the "Dong study" that found levothyroxine generics to be bioequivalent to Synthroid




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts